These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 20144066

  • 1. Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine.
    Miyagawa K, Dohi Y, Nakazawa A, Sugiura T, Yamashita S, Sato K, Kimura G.
    Clin Exp Hypertens; 2010 Jan; 32(1):1-7. PubMed ID: 20144066
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease.
    Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K.
    Hypertens Res; 2009 Apr; 32(4):270-5. PubMed ID: 19262495
    [Abstract] [Full Text] [Related]

  • 3. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K.
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [Abstract] [Full Text] [Related]

  • 4. Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria.
    Saito F, Fujita H, Takahashi A, Ichiyama I, Harasawa S, Oiwa K, Takahashi N, Otsuka Y, Uchiyama T, Kanmatsuse K, Kushiro T.
    Hypertens Res; 2007 Jan; 30(1):39-47. PubMed ID: 17460370
    [Abstract] [Full Text] [Related]

  • 5. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
    Maeda A, Tamura K, Kanaoka T, Ohsawa M, Haku S, Azushima K, Dejima T, Wakui H, Yanagi M, Okano Y, Fujikawa T, Toya Y, Mizushima S, Tochikubo O, Umemura S.
    Clin Exp Hypertens; 2012 Jan; 34(4):249-57. PubMed ID: 22571446
    [Abstract] [Full Text] [Related]

  • 6. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy.
    Brachmann J, Ansari A, Mahla G, Handrock R, Klebs S.
    Adv Ther; 2008 May; 25(5):399-411. PubMed ID: 18465097
    [Abstract] [Full Text] [Related]

  • 7. Effects of combination therapy with angiotensin II type I receptor blockers and calcium channel blockers on renal function in hypertensive patients/a retrospective, "real-world" comparative study.
    Yamada H, Suga N, Maeda K, Kimura Y, Miura N, Futenma A, Imai H.
    Arzneimittelforschung; 2010 May; 60(2):64-70. PubMed ID: 20329653
    [Abstract] [Full Text] [Related]

  • 8. Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
    Morimoto S, Maki K, Aota Y, Sakuma T, Iwasaka T.
    Hypertens Res; 2008 Aug; 31(8):1603-10. PubMed ID: 18971536
    [Abstract] [Full Text] [Related]

  • 9. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study.
    Ohishi M, Takagi T, Ito N, Terai M, Tatara Y, Hayashi N, Shiota A, Katsuya T, Rakugi H, Ogihara T.
    Hypertens Res; 2007 Sep; 30(9):797-806. PubMed ID: 18037772
    [Abstract] [Full Text] [Related]

  • 10. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
    Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchi Y, Uchida S, Kuwahara M, Yamazaki T, Japanese Lasartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators.
    Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
    [Abstract] [Full Text] [Related]

  • 11. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
    Ishimitsu T, Numabe A, Masuda T, Akabane T, Okamura A, Minami J, Matsuoka H.
    Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K, OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Group.
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [Abstract] [Full Text] [Related]

  • 13. Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease.
    Abe M, Okada K, Maruyama N, Matsumoto S, Maruyama T, Fujita T, Matsumoto K, Soma M.
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1027-37. PubMed ID: 20649501
    [Abstract] [Full Text] [Related]

  • 14. Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria.
    Ando K, Haneda M, Ito S, Kashihara N, Node K, Nangaku M, Shimosawa T, Kishimoto J, Fujita T.
    Cardiovasc Drugs Ther; 2011 Aug; 25(4):341-7. PubMed ID: 21637969
    [Abstract] [Full Text] [Related]

  • 15. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M.
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [Abstract] [Full Text] [Related]

  • 16. Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients.
    Ishimitsu T, Kobayashi T, Honda T, Takahashi M, Minami J, Ohta S, Inada H, Yoshii M, Ono H, Matsuoka H.
    Hypertens Res; 2005 Apr; 28(4):351-9. PubMed ID: 16138566
    [Abstract] [Full Text] [Related]

  • 17. Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
    Ohishi M, Takeya Y, Tatara Y, Yamamoto K, Onishi M, Maekawa Y, Kamide K, Rakugi H.
    Hypertens Res; 2010 Nov; 33(11):1150-4. PubMed ID: 20703230
    [Abstract] [Full Text] [Related]

  • 18. Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
    Kojima M, Okubo S, Mizubayashi R, Isaka N, Machida H, Okamoto S, Hirota H, Takeuchi M, Kato T, Nakatani K, Mizuno O, Miyagawa K, Makino K, Okura T, Dohi Y, Ito M, Kimura G.
    Nephrol Dial Transplant; 2013 Jul; 28(7):1802-10. PubMed ID: 23535223
    [Abstract] [Full Text] [Related]

  • 19. Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria.
    Abe M, Okada K, Maruyama N, Matsumoto S, Maruyama T, Fujita T, Matsumoto K, Soma M.
    Hypertens Res; 2011 Feb; 34(2):268-73. PubMed ID: 21124330
    [Abstract] [Full Text] [Related]

  • 20. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, Schneider H, Pospiech R.
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.